Skip to main content
Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
40.13
+6.14 (18.06%)
At close: Mar 9, 2026, 4:00 PM EDT
42.18
+2.05 (5.11%)
After-hours: Mar 9, 2026, 7:43 PM EDT

Nanobiotix Revenue

Nanobiotix had revenue of 26.64M EUR in the half year ending June 30, 2025, with 708.93% growth. This brings the company's revenue in the last twelve months to 10.16M, down -75.93% year-over-year. In the year 2024, Nanobiotix had annual revenue of -7.19M, down -119.86%.

Revenue (ttm)
10.16M EUR
Revenue Growth
-75.93%
P/S Ratio
157.64
Revenue / Employee
98,631 EUR
Employees
103
Market Cap
1.88B USD

Revenue Chart

* This company reports financials in EUR.

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024-7.19M-43.40M-119.86%
Dec 31, 202336.21M31.43M658.12%
Dec 31, 20224.78M2.13M80.43%
Dec 31, 20212.65M322.00K13.85%
Dec 31, 20202.33M-216.00K-8.50%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Novavax 1.12B
Harmony Biosciences Holdings 868.45M
Innoviva 411.33M
AnaptysBio 234.60M
Nurix Therapeutics 83.98M
Intellia Therapeutics 67.67M
Nuvation Bio 62.90M
Agios Pharmaceuticals 54.03M
Revenue Rankings

NBTX News

More News